| Dr Jared Adam Hertz, DO | |
|
350 W Main St, Babylon, NY 11702-3417 | |
| (631) 661-2277 | |
| Not Available |
| Full Name | Dr Jared Adam Hertz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 15 Years |
| Location | 350 W Main St, Babylon, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164782108 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 20A11772 (California) | Secondary |
| 207R00000X | Internal Medicine | 263785 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Catholic Home Care | Farmingdale, NY | Home health agency |
| Good Samaritan Hospital Medical Center | West islip, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Babylon Medical Practice, P.c. | 4789598053 | 6 |
News Archive
The researchers from Brigham and Women's Hospital this week have come up with a new study which shows that reducing the inflammation among patients who have already had a heart attack before could prevent the risk of getting more cardiovascular events. The study is published in the latest issue of the New England Journal of Medicine.
The 30-day window for hospital readmissions - used by the federal government to penalize hospitals believed to provide lower-quality care because patients return to the hospital following discharge - should be reduced to a week or less to more accurately measure factors within a hospital's control, new research from UC Davis has found.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.
In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."
› Verified 5 days ago
| Entity Name | Babylon Medical Practice, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811967805 PECOS PAC ID: 4789598053 Enrollment ID: O20031119000594 |
News Archive
The researchers from Brigham and Women's Hospital this week have come up with a new study which shows that reducing the inflammation among patients who have already had a heart attack before could prevent the risk of getting more cardiovascular events. The study is published in the latest issue of the New England Journal of Medicine.
The 30-day window for hospital readmissions - used by the federal government to penalize hospitals believed to provide lower-quality care because patients return to the hospital following discharge - should be reduced to a week or less to more accurately measure factors within a hospital's control, new research from UC Davis has found.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.
In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."
› Verified 5 days ago
| Entity Name | Jared Hertz Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881393452 PECOS PAC ID: 7810331436 Enrollment ID: O20240221003929 |
News Archive
The researchers from Brigham and Women's Hospital this week have come up with a new study which shows that reducing the inflammation among patients who have already had a heart attack before could prevent the risk of getting more cardiovascular events. The study is published in the latest issue of the New England Journal of Medicine.
The 30-day window for hospital readmissions - used by the federal government to penalize hospitals believed to provide lower-quality care because patients return to the hospital following discharge - should be reduced to a week or less to more accurately measure factors within a hospital's control, new research from UC Davis has found.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.
In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jared Adam Hertz, DO 4 Mallard Dr, Lloyd Harbor, NY 11743-9712 Ph: (646) 246-7377 | Dr Jared Adam Hertz, DO 350 W Main St, Babylon, NY 11702-3417 Ph: (631) 661-2277 |
News Archive
The researchers from Brigham and Women's Hospital this week have come up with a new study which shows that reducing the inflammation among patients who have already had a heart attack before could prevent the risk of getting more cardiovascular events. The study is published in the latest issue of the New England Journal of Medicine.
The 30-day window for hospital readmissions - used by the federal government to penalize hospitals believed to provide lower-quality care because patients return to the hospital following discharge - should be reduced to a week or less to more accurately measure factors within a hospital's control, new research from UC Davis has found.
Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.
In her latest piece on the New York Times' "Opinionator" blog, author and journalist Tina Rosenberg argues that the terms of Gilead's recent agreement with the Medicines Patent Pool is "confirmation of a dangerous new trend: middle-income countries as a target market for drug makers."
› Verified 5 days ago
Dr. James Anthony Stallone, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W Main St, Suite 234, Babylon, NY 11702 Phone: 631-321-4200 | |
Dr. Claire A Scanlon-kohlroser, MD, MPH Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 400 W Main St, Suite 300, Babylon, NY 11702 Phone: 631-321-6400 | |
Dr. Babak Danesh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W Main St, Suite 300, Babylon, NY 11702 Phone: 631-321-6400 Fax: 631-321-2969 | |
Dr. Addie Dissick, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 W Main St, Suite 110, Babylon, NY 11702 Phone: 631-376-2663 Fax: 631-376-5907 | |
Dr. James George Kohlroser, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W Main St, Suite 300, Babylon, NY 11702 Phone: 631-321-6400 Fax: 631-321-2969 | |
Frank T. Pollaro, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 W Main St, Babylon, NY 11702 Phone: 631-661-2277 |